03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
21:12 , Apr 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting MLL5 could help treat RNA viral infections. In primary mouse macrophages infected with vesicular stomatitis virus (VSV) or Sendai virus, knockout of MLL5 decreased levels...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Peroxisome proliferation-activated receptor-g (PPARG; PPARg); myeloid-lymphoma or mixed-lineage 5 (MLL5); 5ʹ-3ʹ exoribonuclease 2 (XRN2) In vitro and mouse studies suggest activating genes involved...